DK3166973T3 - Immunstimulerende monoklonale antistoffer mod human interleukin-2 - Google Patents
Immunstimulerende monoklonale antistoffer mod human interleukin-2 Download PDFInfo
- Publication number
- DK3166973T3 DK3166973T3 DK15759938.2T DK15759938T DK3166973T3 DK 3166973 T3 DK3166973 T3 DK 3166973T3 DK 15759938 T DK15759938 T DK 15759938T DK 3166973 T3 DK3166973 T3 DK 3166973T3
- Authority
- DK
- Denmark
- Prior art keywords
- immunstimulating
- monoclonal antibodies
- antibodies against
- against human
- human interleukin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14176619 | 2014-07-10 | ||
| PCT/IB2015/055226 WO2016005950A1 (en) | 2014-07-10 | 2015-07-10 | Immune-stimulating monoclonal antibodies against human interleukin-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3166973T3 true DK3166973T3 (da) | 2020-04-06 |
Family
ID=51162588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15759938.2T DK3166973T3 (da) | 2014-07-10 | 2015-07-10 | Immunstimulerende monoklonale antistoffer mod human interleukin-2 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10894828B2 (da) |
| EP (2) | EP3166973B1 (da) |
| JP (1) | JP7209464B2 (da) |
| CN (1) | CN106604932A (da) |
| AU (1) | AU2015287227B2 (da) |
| CA (1) | CA2954476C (da) |
| DK (1) | DK3166973T3 (da) |
| ES (1) | ES2779977T3 (da) |
| WO (1) | WO2016005950A1 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA43859A (fr) | 2016-01-11 | 2018-11-21 | Novartis Ag | Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion |
| BR112019005944A2 (pt) * | 2016-09-28 | 2019-06-11 | Musc Foudation For Res Development | anticorpos que se ligam à interleucina 2 e usos dos mesmos |
| GB201621806D0 (en) * | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| WO2018156955A1 (en) * | 2017-02-23 | 2018-08-30 | City Of Hope | Methods for in vivo expansion of cd8+ t cells and prevention or treatment of gvhd |
| KR20190132665A (ko) * | 2017-03-23 | 2019-11-28 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 항-C5a 항체 및 이의 용도 |
| CN110914297B (zh) * | 2017-05-25 | 2023-06-06 | 基础科学研究院 | 抗人白细胞介素2抗体及其用途 |
| CN112020510A (zh) | 2018-03-19 | 2020-12-01 | 茂体外尔公司 | 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物 |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| CN115768483A (zh) | 2020-01-13 | 2023-03-07 | 西纳福克斯股份有限公司 | 抗体与免疫细胞衔接器的缀合物 |
| KR20240014590A (ko) | 2020-02-16 | 2024-02-01 | 아울로스 바이오사이언스 인코포레이티드 | 조작된 항-il-2 항체 |
| JP2024506022A (ja) | 2021-02-08 | 2024-02-08 | シンアフィックス ビー．ブイ． | 多機能性抗体 |
| WO2023061005A1 (zh) | 2021-10-14 | 2023-04-20 | 徕特康(苏州)生物制药有限公司 | 新型抗体-细胞因子融合蛋白及其制备方法和用途 |
| US11773160B1 (en) | 2022-08-05 | 2023-10-03 | Anaveon AG | Immune-stimulating IL-2 fusion proteins |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ210634A (en) * | 1983-12-23 | 1989-05-29 | Hoffmann La Roche | Purification of recombinant human interleukin - 2; pharmaceutical compositions |
| JPS62269698A (ja) * | 1986-03-17 | 1987-11-24 | エフ．ホフマン ― ラ ロシュ アーゲー | Ｉｌ−２蛋白質に対するモノクロ−ナル抗体 |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| ES2308787T3 (es) | 1996-08-16 | 2008-12-01 | Schering Corporation | Antigenos de superficie de celular de mamiferos; reactivos relacionados. |
| DE69839147T2 (de) | 1997-06-12 | 2009-02-19 | Novartis International Pharmaceutical Ltd. | Künstliche antikörperpolypeptide |
| WO2004060319A2 (en) | 2002-12-30 | 2004-07-22 | 3M Innovative Properties Company | Immunostimulatory combinations |
| EP1765402A2 (en) | 2004-06-04 | 2007-03-28 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| AU2006254333B2 (en) * | 2005-06-01 | 2011-02-17 | Amgen Research (Munich) Gmbh | Anti-IL2 antibodies |
| CN104072614B (zh) * | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
| WO2007095643A2 (en) * | 2006-02-16 | 2007-08-23 | Nascent Biologics, Inc. | Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject |
| CN101045923B (zh) * | 2006-03-31 | 2011-11-23 | 沈阳三生制药有限责任公司 | 生产一种白细胞介素类似物的方法 |
| RU2531758C2 (ru) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
| LT3042917T (lt) | 2010-08-12 | 2018-05-10 | Eli Lilly And Company | Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas |
| LT3489255T (lt) | 2011-02-10 | 2021-08-25 | Roche Glycart Ag | Mutantiniai interleukino-2 polipeptidai |
| WO2013157105A1 (ja) * | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 |
| CN103566377A (zh) | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| WO2015109212A1 (en) * | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
-
2015
- 2015-07-10 CN CN201580048027.0A patent/CN106604932A/zh active Pending
- 2015-07-10 WO PCT/IB2015/055226 patent/WO2016005950A1/en active Application Filing
- 2015-07-10 EP EP15759938.2A patent/EP3166973B1/en active Active
- 2015-07-10 DK DK15759938.2T patent/DK3166973T3/da active
- 2015-07-10 JP JP2017501280A patent/JP7209464B2/ja active Active
- 2015-07-10 US US15/324,468 patent/US10894828B2/en active Active
- 2015-07-10 ES ES15759938T patent/ES2779977T3/es active Active
- 2015-07-10 AU AU2015287227A patent/AU2015287227B2/en active Active
- 2015-07-10 EP EP20158066.9A patent/EP3693389A1/en active Pending
- 2015-07-10 CA CA2954476A patent/CA2954476C/en active Active
-
2020
- 2020-12-22 US US17/131,221 patent/US20210230269A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210230269A1 (en) | 2021-07-29 |
| CA2954476C (en) | 2023-09-19 |
| ES2779977T3 (es) | 2020-08-21 |
| EP3166973A1 (en) | 2017-05-17 |
| EP3693389A1 (en) | 2020-08-12 |
| US10894828B2 (en) | 2021-01-19 |
| CA2954476A1 (en) | 2016-01-14 |
| EP3166973B1 (en) | 2020-02-19 |
| JP2017525343A (ja) | 2017-09-07 |
| EP3693389A9 (en) | 2021-04-07 |
| WO2016005950A1 (en) | 2016-01-14 |
| US20170183403A1 (en) | 2017-06-29 |
| AU2015287227A8 (en) | 2017-02-16 |
| AU2015287227B2 (en) | 2021-02-18 |
| CN106604932A (zh) | 2017-04-26 |
| AU2015287227A1 (en) | 2017-02-09 |
| JP7209464B2 (ja) | 2023-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000370A1 (es) | Nuevos anticuerpos anti-pd-1 | |
| CL2018000281A1 (es) | Anticuerpos monoclonales contra bcma | |
| DK4050034T3 (da) | Cd3-bindende antistoffer | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| DK3332006T3 (da) | Hidtil ukendte anti-PD-L1-antistoffer | |
| BR112017001385A2 (pt) | anticorpos anti-pd-1 | |
| DK3273992T3 (da) | Antistoffer mod ICOS | |
| DK3283110T3 (da) | Antistoffer rettet mod interleukin-36-receptor (il-36r) | |
| DK3166973T3 (da) | Immunstimulerende monoklonale antistoffer mod human interleukin-2 | |
| DK3191517T3 (da) | Krydsreaktive siglec-antistoffer | |
| DK3229838T3 (da) | Anti-C10orf54-antistoffer og anvendelser deraf | |
| DK3221363T3 (da) | Antistoffer mod cd73 og anvendelser deraf | |
| DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
| DK3309174T3 (da) | ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf | |
| DK3575315T3 (da) | Kimære antigenreceptorer | |
| DK3209685T3 (da) | Enkeltdomæneantistoffer rettet mod intracellulære antigener | |
| DK3248986T3 (da) | Variable immunoglobulindomæner | |
| DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
| DK3131928T3 (da) | Trifunktionelt antigenbindende molekyle | |
| KR20180085002A (ko) | 인간화된 항-cll-1 항체 | |
| DK3157559T3 (da) | Anti-axl-antistoffer | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| CL2016001742A1 (es) | Anticuerpos anti-baff novedosos | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| DK3215530T3 (da) | Forbedrede il-6 antistoffer |